Understanding the mechanisms by which tumour cells adapt or succumb to targeted therapies is crucial to improving cancer treatment. A study in this issue of Nature Metabolism demonstrates how microRNAs, metabolic pathways and pseudohypoxia play a major role in the drug tolerance to epidermal growth factor receptor (EGFR) inhibitors in lung adenocarcinoma.
Mir-roring hypoxia in EGFR-TKI tolerance
Pardini B.Last
2019-01-01
Abstract
Understanding the mechanisms by which tumour cells adapt or succumb to targeted therapies is crucial to improving cancer treatment. A study in this issue of Nature Metabolism demonstrates how microRNAs, metabolic pathways and pseudohypoxia play a major role in the drug tolerance to epidermal growth factor receptor (EGFR) inhibitors in lung adenocarcinoma.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Calin and Pardini Nature metabolism.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
724.61 kB
Formato
Adobe PDF
|
724.61 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
